The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.
 
Laurence Buisseret
No Relationships to Disclose
 
Sylvie Rottey
No Relationships to Disclose
 
Johann S. De Bono
Employment - Institute of Cancer Research
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
 
Ariane Migeotte
No Relationships to Disclose
 
Brant Delafontaine
No Relationships to Disclose
 
Thubeena Manickavasagar
No Relationships to Disclose
 
Chiara Martinoli
Employment - ITeos Therapeutics
Stock and Other Ownership Interests - ITeos Therapeutics
Consulting or Advisory Role - ITeos Therapeutics
 
Noémie Wald
Employment - ITeos Therapeutics
Stock and Other Ownership Interests - ITeos Therapeutics
Patents, Royalties, Other Intellectual Property - Patent
Travel, Accommodations, Expenses - ITeos Therapeutics
 
Maura Rossetti
Employment - ITeos Therapeutics
 
Esha A. Gangolli
Employment - Clovis Oncology; ITeos Therapeutics
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Dexcom; Guardant Health; Johnson & Johnson; Novartis
Patents, Royalties, Other Intellectual Property - Patents from CuraGen Corp
Travel, Accommodations, Expenses - Clovis Oncology
 
Erol Wiegert
Employment - ITeos Therapeutics
 
Nicola McIntyre
Stock and Other Ownership Interests - GlaxoSmithKline
Consulting or Advisory Role - Achilles Therapeutics; ASLAN Pharmaceuticals; Cerecin; Evgen; Galecto; ITeos Therapeutics
Travel, Accommodations, Expenses - ASLAN Pharmaceuticals
 
Joanne J. Lager
Employment - ITeos Therapeutics; Sanofi; Sanofi
Leadership - ITeos Therapeutics
Stock and Other Ownership Interests - ITeos Therapeutics
Patents, Royalties, Other Intellectual Property - iTeos Therapeutics (Inst)
Travel, Accommodations, Expenses - ITeos Therapeutics
 
Jean-Pascal H. Machiels
Consulting or Advisory Role - ALX Oncology; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CUE Biopharma; Debiopharm Group; Incyte; Innate Pharma; Janssen; Merck Serono; Merck Sharp & Dohme; Nanobiotix; Novartis; Pfizer; Roche
Research Funding - Bayer; Janssen; Novartis; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer